Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma <i>In Situ</i> Induces Synthetic Lethality and ChemopreventionReem Ali, Srinivasan Madhusudan, Vimla Band et al.|Cancer Research|2018Cited by 31
The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situAbdulbaqi Al-Kawaz, Emad A. Rakha, Islam M. Miligy et al.|Breast Cancer Research and Treatment|2021Cited by 7
Immune infiltration, aggressive pathology, and poor survival outcomes in RECQL helicase deficient breast cancersAyat Lashen, Srinivasan Madhusudan, Abdulbaqi Al-Kawaz et al.|Neoplasia|2023Cited by 5
The frequency and clinical significance of DNA polymerase beta (POLβ) expression in breast ductal carcinoma in situ (DCIS)Abdulbaqi Al-Kawaz, Emad A. Rakha, Andrew R. Green et al.|Breast Cancer Research and Treatment|2021Cited by 2